Characterization of a cohort of metastatic lung cancer patients harboring
KRAS
PD-L1
immunotherapy
lung adenocarcinoma
non-small cell lung cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
06
2023
accepted:
02
10
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
Approximately 20% of lung adenocarcinomas harbor activating mutations at
Identifiants
pubmed: 37916173
doi: 10.3389/fonc.2023.1239000
pmc: PMC10616300
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1239000Informations de copyright
Copyright © 2023 Notario, Cucurull, Cerdà, Sanz, Carcereny, Muñoz-Mármol, Hernández, Domènech, Morán, Sánchez-Céspedes, Costa, Mate, Esteve and Saigí.
Déclaration de conflit d'intérêts
TM reports Consulting/Advisory Role fees by Roche, Bristol Myers, Boehringer, and Astra Zeneca; Research Funding Grant by Kyowa Kirin and Janssen, all of them unrelated with the current work. MS reports a sponsored research agreement with Merck Serono and Roche Farma outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lung Cancer. 2021 May;155:163-169
pubmed: 33838467
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Mol Oncol. 2021 Apr;15(4):887-900
pubmed: 33342055
Front Oncol. 2022 Jan 13;11:793121
pubmed: 35096591
Transl Lung Cancer Res. 2021 Feb;10(2):737-752
pubmed: 33718018
Br J Cancer. 2019 Jan;120(1):57-62
pubmed: 30377342
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Ann Oncol. 2022 Oct;33(10):1029-1040
pubmed: 35872166
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186